Patents Examined by Traviss C. McIntosh, III
  • Aminoglycosides and uses thereof
    Patent number: 11414450
    Abstract: Provided herein are aminoglycoside compounds, such as compounds of formula (I), (II), (III), (IV), (IVa), (V), (VI), (VIIa), or (VIIb) or pharmaceutically acceptable salts, solvates, stereoisomers, or tautomers of any of the foregoing, useful as therapeutic or prophylactic agents. Also provided herein are methods for their preparation. The compounds may be useful in treating a bacterial infection in a subject, for example a Gram-negative bacterial infection.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: August 16, 2022
    Assignee: REVAGENIX, INC.
    Inventors: Logan Andrews, Andrew Calabrese, Timothy Robert Kane, Ryan Cirz, Frederick Cohen, Michael Lopez, John Knox, Nikolai Evdokimov
  • Thiazole-5-carboxylic acid derivative and preparation method and use thereof
    Patent number: 11401247
    Abstract: The present disclosure relates to a thiazole-5-carboxylic acid derivative represented by Formula (I), a stereoisomer and/or pharmaceutically acceptable salt thereof. The compound of Formula (I), the stereoisomer and/or pharmaceutically acceptable salt thereof of the present disclosure can be used to prepare a medicament for preventing or treating hyperuricemia and/or gout, and can be prepared into dosage forms for various administration routes. The compounds provided in the present disclosure have good tolerance, safety and excellent uric acid-lowering activity.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: August 2, 2022
    Assignee: XIANGBEI WELMAN PHARMACEUTICAL CO., LTD
    Inventors: Haiyong Wang, Mingjie Sun
  • Cyclic dinucleotide compound and uses thereof
    Patent number: 11401295
    Abstract: Provided are a compound of formula (I), an optical isomer thereof, a pharmaceutically acceptable salt thereof, uses of said compound acting as a STING agonist.
    Type: Grant
    Filed: October 12, 2019
    Date of Patent: August 2, 2022
    Assignees: SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD., JIANGXI JEMINCARE GROUP CO., LTD.
    Inventors: Shuchun Guo, Jianbiao Peng, Yang Liu, Haibing Guo
  • Methods for treating and virus infections
    Patent number: 11382926
    Abstract: Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: July 12, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Michael O'Neil Hanrahan Clarke, Joy Yang Feng, Robert Jordan, Richard L. Mackman, Adrian S. Ray, Dustin Siegel
  • Galactoside inhibitor of galectins
    Patent number: 11377464
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: September 11, 2020
    Date of Patent: July 5, 2022
    Assignee: Galecto Biotech AB
    Inventors: Thomas Brimert, Richard Johnsson, Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • Crystalline form of Remdesivir
    Patent number: 11377456
    Abstract: The present invention provides a novel crystalline form of remdesivir, remdesivir Form APO-I, including remdesivir and dimethyl sulfoxide, compositions and processes for the preparation thereof, the use of this crystalline form in the treatment of a viral infection, and methods of treating viral infections using the same, and in particular, a viral infection caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2).
    Type: Grant
    Filed: May 25, 2021
    Date of Patent: July 5, 2022
    Assignee: Apotex Inc.
    Inventors: Fabio E. S. Souza, Alexander J. Stirk, Allan W. Rey
  • Analogs of the natural product icariin
    Patent number: 11377466
    Abstract: Provided herein are analogs of the natural product icariin represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The analogs can be used to modulate (e.g., inhibit, such as by competitive inhibition) PDE5 and thereby treat a wide range of PDE5-mediated diseases, including cardiovascular, gastrointestinal, pulmonary, musculoskeletal, neurological and reproductive diseases. Also provided herein are compositions and methods including compounds of Structural Formula (I).
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: July 5, 2022
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Yasmin Chau, Fu-Shuang Li, Jing-Ke Weng
  • Immunodulating small molecules
    Patent number: 11364253
    Abstract: The present invention includes novel compositions and methods for treating comprising a compound with the Formula I: where n=0-5; X?NH, O, S, CH2; Y=Phenyl, a phenyl group substituted with at least one methyl, a phenyl group substituted with at least one nitro, a phenyl group substituted with at least one nitrogen, a phenyl group substituted with at least one boron, aryl, substituted aryl, heteroaryl, four to six membered cycloalkyl, four to six membered heterocycloalkyl; R?H, C(O)R2, SO2R2; R1?H, C(O)R2, SO2R2; R2=Ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, NH2, NR3R4, R3, R4=Ethyl, methyl, isopropyl, n-propyl, t-butyl, n-butyl, three to six membered cycloalkyl and Z?NH, O, S, CH2 or none, wherein the amount of the compound is selected to either inhibit or activate the immune response.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: June 21, 2022
    Assignee: AYUVIS RESEARCH, INC.
    Inventors: Suchismita Acharya, Pragnya Das, Beamon Agarwal
  • Method for efficient production of psicose
    Patent number: 11358980
    Abstract: The present invention relates to a method for effectively utilizing fructose raffinate obtained in the process for separating psicose conversion product with a high purity chromatography in the process for preparing psicose, and more specifically, it is utilized for preparation of fructose-containing raw material solution for preparation of psicose by putting fructose raffinate obtained in the process for preparing psicose into the process for preparing fructose.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: June 14, 2022
    Assignee: SAMYANG CORPORATION
    Inventors: Ji Won Park, Sung Won Park, Chong Jin Park
  • Antibacterial compounds, compositions thereof, and methods using same
    Patent number: 11339184
    Abstract: The present disclosure includes novel compounds useful as antimicrobial agents. The present disclosure further includes methods useful. The present disclosure further includes compositions and methods for treating or preventing a bacterial infection. The present disclosure further includes compositions and methods useful for preventing or reducing the growth or proliferation of microorganisms.
    Type: Grant
    Filed: July 23, 2020
    Date of Patent: May 24, 2022
    Assignee: The Rockefeller University
    Inventors: Sean F. Brady, James Peek
  • Compounds and methods for treating osteoarthritis
    Patent number: 11332490
    Abstract: Disclosed herein are substrates and/or inhibitors of endo-O-sulfatase 1 (Sulf-1). According to some embodiments, the substrates and/or inhibitors of Sulf-1 are compounds of formula (I) or (II), In formula (I) or (II), n is 2 or 3; X is methylene, O, or N; R1 is —SO3M, or —SO2NH2; R2 is C1-6 alkyl or C1-6 alkylamine; and M is a monovalent cation selected from the group consisting of lithium, sodium, potassium, and ammonium. Also encompasses herein are methods of identifying and treating a subject having or suspected of having osteoarthritis.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: May 17, 2022
    Assignee: ACADEMIA SINICA
    Inventors: Shang-Cheng Hung, Chi-Huey Wong, Ting-Jen Cheng
  • E-selectin antagonist compounds, compositions, and methods of use
    Patent number: 11332491
    Abstract: Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: May 17, 2022
    Assignee: GLYCOMIMETICS, INC.
    Inventors: John L. Magnani, Arun K. Sarkar, Myung-Gi Baek, Frank E. Anderson, III, Yanhong Li
  • CD73 inhibitors and therapeutic uses thereof
    Patent number: 11332492
    Abstract: This application discloses CD73 inhibitors represented by the general formula (I) and analogs thereof, pharmaceutical compositions containing these compounds, methods of preparing them, and use of these compounds as therapeutic agents for the treatment of diseases or conditions associated with CD73 activity, such as various cancers.
    Type: Grant
    Filed: August 28, 2019
    Date of Patent: May 17, 2022
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Jian Liu, Heping Wu, Linghang Zhuang, Suxing Liu, Rumin Zhang, Feng He, Weikang Tao
  • N4-hydroxycytidine and derivatives and anti-viral uses related thereto
    Patent number: 11331331
    Abstract: This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, such as Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infection with the disclosed compounds.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: May 17, 2022
    Assignee: Emory University
    Inventors: George R. Painter, Gregory R. Bluemling, Michael G. Natchus, David Guthrie
  • Glycoside compound and preparation method therefor, composition, application, and intermediate
    Patent number: 11325937
    Abstract: The present invention discloses a glycoside compound represented by Formula III, and a preparation method, a composition, use and an intermediate thereof. The glycoside compound provided in the present invention has simple preparation method, can significantly increase the expression of VEGF-A mRNA, and is effective in promoting the angiogenesis. This provides a reliable guarantee for the development of drugs with pro-angiogenic activity for treating cerebral infarction cerebral stroke, myocardial infarction, and ischemic microcirculatory disturbance of lower limbs.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: May 10, 2022
    Assignee: SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED
    Inventors: Guoqiang Lin, Jiange Zhang, Ping Tian, Chenguo Feng, Changsen Zhan, Junjie Zhou
  • Triterpene saponin analogues
    Patent number: 11324821
    Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases and cancers.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: May 10, 2022
    Assignee: ADJUVANCE TECHNOLOGIES, INC.
    Inventors: J Tyler Martin, Jeffrey Gardner
  • Aminoglycoside derivatives and uses thereof in treating genetic disorders
    Patent number: 11306115
    Abstract: Novel pseudo-disaccharide and pseudo-trisaccharide aminoglycosides, represented by Formulae I or Ia, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic diseases and disorders, such as diseases and disorders associated with stop codon mutations.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: April 19, 2022
    Assignee: ELOXX PHARMACEUTICALS LTD.
    Inventor: Timor Baasov
  • Conjugated antisense compounds and their use
    Patent number: 11299736
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: April 12, 2022
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Substituted pyridopyrrolopyrimidine ribonucleosides for therapeutic uses
    Patent number: 11299510
    Abstract: Substituted pyridopyrrolopyrimidine ribonucleosides of general formula I, wherein R is as described in the independent claim, preferably R is selected from the group comprising thiophen-3-yl, furan-2-yl, furan-3-yl, benzofuran-2-yl, methylsulfanyl, methoxy, amino, dimethylamino, methyl; and pharmaceutically acceptable salt thereof, their optical isomers and mixtures of such optical isomers. Compounds according to the invention show strong cytostatic and cytotoxic effects on cell lines of tumor origin in a wide variety of diseases including tumors of different histogenetic origin.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: April 12, 2022
    Assignees: USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I., UNIVERZITA PALACKEHO V OLOMOUCI
    Inventors: Lucia Veselovska, Michal Hocek, Marian Hajduch, Petr Dzubak
  • Processes for preparing sorbose from glucose
    Patent number: 11292806
    Abstract: Processes for converting glucose to sorbose with tailored selectivity. The processes include contacting glucose with a silica-containing structure that includes a zeolite having a topology of a 10-membered ring or smaller and Lewis acidic M4+ framework centers, wherein M is Ti, Sn, Zr, or Hf. Contacting the glucose is conducted under reaction conditions sufficient to isomerize the glucose to sorbose.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: April 5, 2022
    Assignee: Purdue Research Foundation
    Inventors: Rajamani Gounder, Michael Jonathan Cordon, Alyssa M. LaRue, Zige Huang